Phenotypic Precision Medicine VL

The Implementation of PSMA Theranostics in Clinical Practice - Oliver Sartor

Details
Oliver Sartor joins Alicia Morgans in a discussion on the implementation of PSMA theranostics and treating patients with lutetium in clinical practices. Drs Morgans and Sartor talk through the logistics of this integration, patient selection, and treatment choice for prolonging survival and improving quality of life. Dr. Sartor also highlights potential novel expanded indications that we may see i...

A Urologist's Perspective On the Integration of Lutetium Into Clinical Practices - Neal Shore

Details
Urologist Neal Shore joins Alicia Morgans in a discussion on the integration of lutetium into clinical practices. Dr. Shore reviews the phase 3 VISION trial which led to the approval of Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. They discuss steps to thoughtfully and practically, integrate this new therapeutic into our treatment paradigm. Biographies: Neal Shore, MD...

Clinical Implementation of Pluvicto™ (177Lu-PSMA-617) - Michael Morris

Details
Michael Morris joins Alicia Morgans to discuss the clinical implementation of Pluvicto™ (177Lu-PSMA-617) in a way that ensures equity to all patients, regardless of the many factors that could disrupt access. They discuss equity of distribution to all those patients who need it and the availability of PSMA PET scans. Biographies: Michael Morris, MD, Medical Oncologist Clinical Director, Genitourin...

Pluvicto™ (177Lu-PSMA-617) Indications for Clinical Use in PSMA Positive Metastatic Castration-Resistant Prostate Cancer mCRPC - Oliver Sartor

Details
Oliver Sartor joins Phillip Koo to discuss the United State FDA approval of Pluvicto™ (177Lu-PSMA-617) as the first targeted radioligand therapy for the treatment of PSMA positive metastatic castration-resistant prostate cancer (mCRPC). They discuss currently enrolling in clinical trials with Pluvicto in the pre-chemotherapy treated mCRPC patient population. They look further into the future discu...

Appropriate Use Criteria for PSMA PET Imaging - Hossein Jadvar

Details
Phillip Koo is joined by Hossein Jadvar to discuss the Appropriate Use Criteria (AUC) for PSMA PET in prostate cancer. Dr. Jadvar, the first author of the publication, discusses the process of developing the AUC for PSMA PET in prostate cancer and reviews 11 clinical scenarios that may be encountered by ordering professionals when they want to consult the AUC for ordering their imaging. To guide r...

Theranostics - Taking Over Prostate Cancer Care? - Phillip H. Kuo

Details
In this LUGPA CME presentation, Dr Phillip Kuo presents theranostics and its role in prostate cancer treatment. He provides a brief introduction into theranostics, a focus on PSMA, highlighting some select theranostic trials, then delves into a broader vision of what theranostics can mean, particularly to the nuclear medicine committee and PSMA. Biographies: Phillip H. Kuo, MD, Ph.D., Professor of...

PSMAfore Trial - Evaluating 177Lu-PSMA-617 in Chemotherapy-Naïve mCRPC Patients – Michael Morris

Details
Alicia Morgans and Michael Morris, discuss the PSMAfore trial in progress. At the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Morris provided a summary of the PSMAfore trial which examines the role of [177Lu]Lu-PSMA-617 in taxane-naïve patients with mCRPC. Dr. Morris reviews the radiographic progression-free survival (rPFS) data from the VISION trial and the complementary dat...

Pain and Symptomatic Skeletal Events Reported in the VISION Trial – Oliver Sartor

Details
Alicia Morgans and Oliver Sartor discuss additional data from the VISION trial that was recently presented at ESMO 2021. Dr. Sartor discusses the health-related quality of life findings from the VISON specifically pain and symptomatic skeletal events. Dr. Sartor offers the background on the VISION trial, while also describing the patient cohorts. Dr. Sartor discusses how the trial patients randomi...

Phenotypic Expression of Prostate Specific Membrane Antigen (PSMA) - Evan Yu

Details
Phillip Koo and Evan Yu, discuss the phenotypic expression of PSMA. Phenotypic precision medicine guides physicians in looking at the molecular characteristics of a tumor to identify the optimal personalized treatment for the patient. Drs. Yu and Koo discuss the use of PSMA-PET/CT imaging that may fill the critical gaps in prostate cancer staging and as a biomarker for metabolic concordance or res...

Transforming The Standard of Care for Men With Advanced-Stage PSMA-Positive mCRPC, Published Results from the Phase III VISION Trial - Oliver Sartor

Details
Oliver Sartor, MD, joins Charles Ryan, MD in a conversation about the New England Journal of Medicine publication "Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer" known as the VISION trial. The VISION Trial is an international, open-label, phase 3 trial evaluating 177Lu-PSMA-617 in patients who had metastatic castration-resistant prostate cancer previously treated with a...
email news signup